6-Methoxy-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 香豆素及其衍生物
• 英文名称: 6-Methoxy-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-2-one
• 化学式: C₁₆H₁₈O₉
• 分子量: 354.31
• InChiKey: SGTCGCCQZOUMJJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  25
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  135
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Composition for preventing, improving or treating postmenopausal osteoporosis comprising scopolin
  申请人：DONG WOO DANG CO., LTD

  公开号：US10226477B2

  公开（公告）日：2019-03-12

  Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.

  本发明提供了一种用于预防、改善或治疗妇女绝经后骨质疏松症的药物组合物，该组合物包括作为活性成分的东莨菪素、其衍生物或其药学上可接受的盐，其中东莨菪素在刺激成骨细胞分化方面具有良好的功效，并且还能有效抑制绝经后骨密度的降低、骨微结构的低密度、血液中骨形成标志物的降低以及骨吸收标志物的增加。因此，东莨菪素及其作为活性成分的组合物有望作为药物制剂用于预防、改善或治疗妇女绝经后骨质疏松症。
• NOVEL USE FOR SCOPOLIN AND DERIVATIVES THEREOF
  申请人：Park Tae Sun

  公开号：US20120322754A1

  公开（公告）日：2012-12-20

  The present invention relates to a novel use for the compound of Chemical formula 1 in order to produce drugs or foods for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like, and to a composition for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like which contains the compound of Chemical formula 1 as an active ingredient, and also to a method for the prevention or treatment of obesity, fatty liver, diabetes, metabolic syndrome or the like comprising the administration of the compound of Chemical formula 1 to a mammal in a therapeutically effective dose. According to the present invention, the compound of Chemical formula 1 has been confirmed to suppress the differentiation of adipocytes, to reduce body weight and the amount of visceral fat, to reduce concentrations of cholesterol, triglycerides, free fatty acids and glucose which are associated with fatty liver and diabetes and the like and to reduce the fatty component in liver tissue, to suppress gene expression associated with obesity in visceral fatty tissue, and to increase the amount of expression of UCP1 and UCP3 which are UCP (uncoupling protein) genes involved in thermogenesis. The compound of Chemical formula 1 can be used to advantage in order to prevent or treat obesity, fatty liver, diabetes, metabolic syndrome and the like since, unlike the obesity treating agents based on synthetic drugs currently in use, it is based on a natural substance and hence entails a very low risk of adverse effects and, additionally, it exhibits its pharmacological effects by regulating the expression of genes associated with obesity rather than exhibiting pharmacological effects by acting on enzymes or the nervous system.
• COMPOSITION FOR PREVENTING, IMPROVING OR TREATING POSTMENOPAUSAL OSTEOPOROSIS COMPRISING SCOPOLIN
  申请人：AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION

  公开号：US20170252363A1

  公开（公告）日：2017-09-07

  Provided is a pharmaceutical composition for preventing, improving, or treating postmenopausal osteoporosis in women, the composition including, as an active ingredient, scopolin, a derivative thereof, or a pharmaceutically acceptable salt thereof, wherein scopolin has good efficacy in stimulating osteoblast differentiation, and is also effective in inhibiting a reduction in bone density after menopause, low density in a bone microstructure, a reduction in a bone formation marker in the blood, and an increase in a bone resorption marker. Therefore, scopolin and the composition including the same as an active ingredient are expected to be useful as pharmaceutical preparations for the prevention, improvement, or treatment of postmenopausal osteoporosis in women.
• US8828954B2
  申请人：——

  公开号：US8828954B2

  公开（公告）日：2014-09-09
• [EN] COMPOSITIONS AND METHODS FOR TREATING HERPESVIRUS INFECTION<br/>[FR] COMPOSITIONS ET MÉTHODES POUR TRAITER UNE INFECTION PAR LE VIRUS DE L'HERPÈS
  申请人：UNIV PENNSYLVANIA

  公开号：WO2015081199A1

  公开（公告）日：2015-06-04

  The invention provides compositions and methods for treating a herpesvirus infection. The invention also provides compositions and methods for treating Kaposi's sarcoma or Kaposi's sarcoma-associated herpes virus infection by administering an effective amount of a compound that inhibits topoisomerases Ilα to an individual in need thereof. For example, the compound that inhibits topoisomerases Ilα is (+)- Rutamarin, an anolog, or a derivative thereof.